[
  {
    "ts": null,
    "headline": "2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves",
    "summary": "Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts.  Furthermore, the pursuit of dividends need not come at the expense of other investment styles.  Here are two examples: Microsoft (NASDAQ: MSFT) and Eli Lilly (NYSE: LLY).",
    "url": "https://finnhub.io/api/news?id=428e5dff75872045cda713dec1fa68e20ddcb3b3f94e12026225c697f35c8638",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734788580,
      "headline": "2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves",
      "id": 132096043,
      "image": "https://g.foolcdn.com/editorial/images/800238/person-working-at-a-desk.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts.  Furthermore, the pursuit of dividends need not come at the expense of other investment styles.  Here are two examples: Microsoft (NASDAQ: MSFT) and Eli Lilly (NYSE: LLY).",
      "url": "https://finnhub.io/api/news?id=428e5dff75872045cda713dec1fa68e20ddcb3b3f94e12026225c697f35c8638"
    }
  },
  {
    "ts": null,
    "headline": "Novo obesity data positive for Eli Lilly and Amgen, says UBS",
    "summary": "UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also",
    "url": "https://finnhub.io/api/news?id=7daf6f13d49aa39a0fb0bd1707c87219e5838015a83bb866ad16198c58c11208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734784243,
      "headline": "Novo obesity data positive for Eli Lilly and Amgen, says UBS",
      "id": 132095943,
      "image": "https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also",
      "url": "https://finnhub.io/api/news?id=7daf6f13d49aa39a0fb0bd1707c87219e5838015a83bb866ad16198c58c11208"
    }
  },
  {
    "ts": null,
    "headline": "Weight loss seen with Novo’s CagriSema weaker than expected, says BofA",
    "summary": "BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE 1 trial at about 20.4% is “essentially in line” with Zepbound at 21%, and not high enough to create a barrier relative to future competition, says the analyst. With that said, the data is still superior to Wegovy and sufficient",
    "url": "https://finnhub.io/api/news?id=d546e645e6b0cb84b34f0e4b46e4a80821a1e0ca5a796f1e9fe6a1597fc17c55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734783925,
      "headline": "Weight loss seen with Novo’s CagriSema weaker than expected, says BofA",
      "id": 132094108,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE 1 trial at about 20.4% is “essentially in line” with Zepbound at 21%, and not high enough to create a barrier relative to future competition, says the analyst. With that said, the data is still superior to Wegovy and sufficient",
      "url": "https://finnhub.io/api/news?id=d546e645e6b0cb84b34f0e4b46e4a80821a1e0ca5a796f1e9fe6a1597fc17c55"
    }
  },
  {
    "ts": null,
    "headline": "Is Now a Good Time to Buy the Dip in Eli Lilly Stock?",
    "summary": "Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.",
    "url": "https://finnhub.io/api/news?id=63247a75cd8441ebd56c4743c6e604aa0e65e73d024b8e9ff7adb5f9c65df01e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734774900,
      "headline": "Is Now a Good Time to Buy the Dip in Eli Lilly Stock?",
      "id": 132091941,
      "image": "https://g.foolcdn.com/editorial/images/801652/gettyimages-1166581794-2.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.",
      "url": "https://finnhub.io/api/news?id=63247a75cd8441ebd56c4743c6e604aa0e65e73d024b8e9ff7adb5f9c65df01e"
    }
  },
  {
    "ts": null,
    "headline": "If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy",
    "summary": "The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors.",
    "url": "https://finnhub.io/api/news?id=d5eae36fb2c4b242a6ff797ba27a3c5c004e126d305bd97ae5534840b428cb85",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734773400,
      "headline": "If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy",
      "id": 132095841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810148/image_1445810148.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors.",
      "url": "https://finnhub.io/api/news?id=d5eae36fb2c4b242a6ff797ba27a3c5c004e126d305bd97ae5534840b428cb85"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
    "summary": "Eli Lilly  said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.  The company said Zepbound, or tirzepatide, is the first and only prescription medicine for adults suffering from this condition.  The drug was launched in the U.S. for the treatment of adults with obesity or who are overweight with weight-related comorbidities in November 2023.",
    "url": "https://finnhub.io/api/news?id=79aa3556c24075d0a73472e2f868f02de69b33c4d6e4df9ef29efa83b2a829cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734743100,
      "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
      "id": 132087588,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.  The company said Zepbound, or tirzepatide, is the first and only prescription medicine for adults suffering from this condition.  The drug was launched in the U.S. for the treatment of adults with obesity or who are overweight with weight-related comorbidities in November 2023.",
      "url": "https://finnhub.io/api/news?id=79aa3556c24075d0a73472e2f868f02de69b33c4d6e4df9ef29efa83b2a829cd"
    }
  }
]